The high levels of ANGPT2 before DAAs were independently related to the risk of HCC recurrence (odds ratio (OR), 1.137; 95% confidence interval (CI), 1.044–1.137; p = 0.003) and occurrence (OR, 1.604; 95% CI, 1.080–2.382; p = 0.019), thus suggesting the possible role of ANGPT2 as a biomarker for identifying patients with cirrhosis at risk of HCC development before the treatment with DAAs (Table 4). This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.